The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook

Soft tissue sarcomas (STS) are a subset of sarcoma, a rare group of heterogeneous malignancies of mesenchymal origin. Current standard of care involves surgical resection with systemic chemotherapy used to treat high-risk localized and metastatic disease. Though clasthe immune system, undergoing immunoediting that alters tumor immunogenicity and the tumor microenvironment. Recent advances with immune checkpoint inhibition have led to clinical trials exploring the efficacy of immunotherapy in treating STS. Results from these trials point to histologic subtype???specific clinical activity of immune checkpoint blockade. In addition, combinatorial strategies adding immune checkpoint inhibition to local or systemic therapies for STS have further increased their efficacy. Targeted immunotherapies using engineered T-cell receptor???based approaches also show increasing promise as treatment options for some patients with STS. MAGE-A4 have high response rates in sarcomas expressing these Future work must focus on identifying primary and acquired mechadoi: 10.6004/jnccn.2022.7027

Automated summary

Soft tissue sarcomas (STS) are rare tumors treated with surgical resection and systemic chemotherapy. Immune checkpoint inhibitors show promise as a potential treatment option for STS, but further research is needed.